Biotechnology
Bota Bio debuted the 2024 FiE and launched its subsidiary HeliaGenesis, focusing on food and nutrition industries
SAN FRANCISCO and HANGZHOU, China, Dec. 12, 2024 /PRNewswire/ -- The 31st Food Ingredients Europe (referred to as FiE) concluded successfully fromNovember 19th to 21st, 2024, in Frankfurt, Germany. The event brought together over 1,500 ingredient manufacturers and more than 25,000 professional bu...
CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...
Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.
CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma
Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life
Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
* ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer withESR1 mutations, aiming to delay disease progression. * The study was presented by the Menarini Group and MEDSIR at the San Ant...
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
* Leading Green CRDMO Driven by Innovation for a Healthier Future * Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organizati...
KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 for Clinical Trial in Sickle Cell Disease (SCD)
SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that preclinical...
CBC Group R-Bridge Healthcare Fund Announces up to US$50 Million Financing for Human Investments Ltd. to Fund Motiva® Market Expansion
* Non-dilutive growth financing of up to US$50 million, with a synthetic royalty feature, and availability linked to achievement of certain sales milestones * Proceeds from the financing will fund Human Investments Ltd.'s expansion of Motiva® devices inAsia * Transaction highlights R-Bridge...
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIP...
Laekna Announces Poster Presentation on Internally Discovered Selective PI3Kα Inhibitor at SABCS 2024
LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) onDecember 13, 2024. The presentation will feature preclinical characterization of LAE11...
Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation
* The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors using the comprehensive generative chemistry engine Chemistry42. * From initiation to preclinical candidate nomination, the program spanned only 12 months, during which approximately 115 molecules...
Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer
Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety profile in heavily pretreated patients with EGFR-mutated NSCLC who had developed resistance to EGFR TKI treatment SHANGHAI, Dec. 11, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical compa...
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion
HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch inBoston ,USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the ...
Call for Application for 2025 Tsinghua Amgen Scholars Program
BEIJING, Dec. 11, 2024 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thro...
2024 PHBS-CJBS Global Pitch Competition Grand Final Held
SHENZHEN, China, Dec. 11, 2024 /PRNewswire/ -- The 2024 PHBS-CJBS Global Pitch Competition, jointly hosted by Peking University HSBC Business School (PHBS) and Cambridge Judge Business School (CJBS), concluded with its grand final on December 5th at PHBS in Shenzhen, China. During the finals...
Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment
DOVER, Del. and EPALINGES, Switzerland, Dec. 10, 2024 /PRNewswire/ -- Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Ach...
【2024 ASH】TransThera Announces the Phase I Study Results of TT-01488, a Novel Non-Covalent BTK Inhibitor, in Patients with Relapsed or Refractory B-cell Malignancies
NANJING, China and GAITHERSBURG, Md., Dec. 10, 2024 /PRNewswire/ -- TransThera Sciences (Nanjing), Inc. (the "TransThera"), a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing innovative small molecule therapies for oncology, ...
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that Prof.Weiming Li, ...
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...
PENTAX Medical obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series
MONTVALE, N.J., Dec. 10, 2024 /PRNewswire/ -- PENTAX Medical, a division of HOYA Group, has obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series—PENTAX Medical Video Colonoscope EC34-i20cL, PENTAX Medical Video Upper GI Scope EG27‑i20c and Right/Left W...
Week's Top Stories
Most Reposted
PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS
[Picked up by 323 media titles]
2024-12-19 13:41Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 309 media titles]
2024-12-20 16:25Magic Compass Group Sponsors 2024 World Taekwondo Poomsae Championship
[Picked up by 308 media titles]
2024-12-19 17:56AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 306 media titles]
2024-12-20 18:11MediSun Energy Joins the Abu Dhabi Sustainable Finance Declaration, Reinforcing Commitment to Sustainable Solutions in the UAE
[Picked up by 290 media titles]
2024-12-18 15:35